Pacific Biosciences Of California (PACB) Cost of Revenue (2011 - 2026)

Pacific Biosciences Of California's Cost of Revenue history runs 16 years deep, the most recent figure standing at $24.3 million for Q1 2026.

• In Q1 2026, Cost of Revenue fell 36.83% year-over-year to $24.3 million; the TTM figure through Mar 2026 stood at $100.0 million (down 21.68% YoY), while the FY2025 annual figure was $114.2 million, down 2.15% from the prior year.
• Cost of Revenue was $24.3 million for Q1 2026 at Pacific Biosciences Of California, down from $28.1 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $48.8 million in Q4 2023 to a low of $18.8 million in Q3 2022.
• Historically, Cost of Revenue has averaged $28.4 million across 5 years, with a median of $28.1 million in 2025.
• Biggest YoY gain for Cost of Revenue was 472.31% in 2022; the steepest drop was 63.48% in 2022.
• A 5-year view of Cost of Revenue shows it stood at $22.2 million in 2022, then jumped by 119.63% to $48.8 million in 2023, then tumbled by 40.22% to $29.2 million in 2024, then retreated by 3.73% to $28.1 million in 2025, then fell by 13.33% to $24.3 million in 2026.
• The last three Cost of Revenue figures came in at $24.3 million (Q1 2026), $28.1 million (Q4 2025), and $22.5 million (Q3 2025), per Business Quant data.